Compare CLWT & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | BRTX |
|---|---|---|
| Founded | 1971 | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 9.7M |
| IPO Year | 1997 | N/A |
| Metric | CLWT | BRTX |
|---|---|---|
| Price | $1.23 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 151.3K | 80.8K |
| Earning Date | 12-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $15,383,000.00 | $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | $12.41 | ★ N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | $0.99 | $0.98 |
| 52 Week High | $1.63 | $2.55 |
| Indicator | CLWT | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 41.90 |
| Support Level | $1.14 | $1.00 |
| Resistance Level | $1.24 | $1.16 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 95.87 | 73.10 |
Euro Tech Holdings Co Ltd is a distributor and manufacturer of technology instruments as well as an environmental engineering services provider. It is engaged in the marketing and trading of water and wastewater related process control, analytical and testing instruments, disinfection equipment, supplies, and related automation systems. There are two operating segments of the company. The Trading and manufacturing segment, which is the key revenue driver, includes distribution of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies and power generation equipment. The Engineering segment includes water and waste-water treatment engineering and air pollution control business. The majority of the revenue is generated from Hong Kong.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.